GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

EuBiologics Co 206650.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

8,090

+2.02%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩149.20bn

FY2016FY2025

Net income

₩41.26bn

FY2016FY2025

Free cash flow

₩32.14bn

FY2016FY2025

Shareholders' equity

₩175.36bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩149.20bn₩96.04bn₩69.37bn₩55.47bn₩39.38bn₩28.49bn₩33.07bn₩24.89bn₩11.57bn₩4.84bn
Research and development₩13.21bn₩13.01bn₩17.88bn₩15.78bn₩16.18bn₩8.09bn₩4.36bn₩2.90bn₩1.20bn₩717.0m
Operating income₩60.66bn₩25.75bn—−₩4.61bn−₩7.23bn−₩5.96bn₩9.81bn₩5.31bn−₩4.35bn−₩6.91bn
Net income₩41.26bn₩19.12bn−₩13.88bn−₩1.10bn−₩27.57bn−₩60.13bn−₩882.0m₩3.78bn−₩4.71bn−₩6.70bn
Diluted earnings per share1,126.69523.26-380.72-30.15-760.15-2,073.58-32.66145.42-188.60-394.23

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩240.23bn₩202.08bn₩151.81bn₩162.07bn₩150.44bn₩155.96bn₩92.77bn₩68.24bn₩26.85bn₩13.49bn
Cash and short-term investments—₩22.85bn₩9.90bn—₩31.54bn₩53.09bn₩9.73bn₩19.36bn₩9.64bn₩1.06bn
Total liabilities₩64.87bn₩70.05bn₩40.43bn₩42.63bn₩30.44bn₩59.08bn₩57.81bn₩42.69bn₩8.70bn₩10.10bn
Debt—₩12.07bn₩13.00bn₩3.60bn₩8.72bn₩22.57bn₩37.35bn₩33.38bn₩3.26bn₩4.57bn
Shareholders' equity₩175.36bn₩132.03bn₩111.37bn₩124.51bn₩120.00bn₩96.88bn₩34.95bn₩25.54bn₩18.15bn₩3.39bn
Shares outstanding37m37m36m36m36m29m27m26m25m17m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩49.10bn₩43.21bn₩26.45bn₩6.44bn−₩7.60bn−₩914.0m₩12.88bn₩2.94bn−₩2.64bn−₩3.69bn
Capital spending−₩16.96bn−₩11.82bn−₩43.66bn−₩25.24bn−₩9.16bn−₩9.94bn−₩27.68bn−₩24.75bn−₩6.65bn−₩460.0m
Free cash flow₩32.14bn₩31.39bn−₩17.21bn−₩18.80bn−₩16.76bn−₩10.85bn−₩14.80bn−₩21.82bn−₩9.29bn−₩4.15bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩33.22bn₩15.64bn₩32.33bn₩41.12bn₩36.23bn₩39.51bn₩36.83bn₩36.15bn
Operating income₩8.58bn₩2.20bn₩13.61bn₩18.91bn₩11.24bn₩16.91bn₩8.04bn₩16.98bn
Net income₩7.50bn₩3.66bn₩414.0m₩17.43bn₩7.73bn₩15.70bn₩8.23bn₩16.09bn
Diluted earnings per share204.3099.7511.27475.79211.03429.61225.29440.45
Cash from operations−₩5.51bn₩2.79bn₩5.61bn₩19.58bn₩6.93bn₩16.99bn₩43.21bn₩12.46bn
Capital spending−₩1.23bn−₩3.29bn−₩7.76bn−₩4.12bn−₩1.90bn−₩3.17bn−₩11.82bn−₩10.51bn
Free cash flow−₩6.74bn−₩494.0m−₩2.15bn₩15.46bn₩5.03bn₩13.81bn₩31.39bn₩1.94bn
Total assets₩239.10bn₩235.16bn₩240.23bn₩232.66bn₩224.32bn₩217.92bn₩202.08bn₩175.42bn
Cash and short-term investments——————₩22.85bn₩14.92bn
Debt——————₩12.07bn₩11.57bn
Shareholders' equity₩181.52bn₩179.72bn₩175.36bn₩173.74bn₩156.01bn₩147.92bn₩132.03bn₩123.93bn

Financial ratios

Data as of 1 Sept 2026

FY2025FY2024FY2023FY2022FY2021
Operating margin40.7%26.8%—-8.3%-18.4%
Net margin27.7%19.9%-20.0%-2.0%-70.0%
Return on equity23.5%14.5%-12.5%-0.9%-23.0%
Return on assets17.2%9.5%-9.1%-0.7%-18.3%
Revenue growth55.4%38.4%25.1%40.8%—
Earnings growth115.9%-237.7%1163.0%-96.0%—
Current ratio3.29x1.93x1.63x1.67x3.11x
Debt to equity—0.06x0.10x0.03x0.05x
Equity ratio73.0%65.3%73.4%76.8%79.8%
Interest coverage61.00x22.62x—-9.08x-8.63x
R&D as a share of sales8.9%13.5%25.8%28.4%41.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue39.1%39.3%57.4%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin35.2%———
Net margin24.6%12.3%-9.7%-10.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2021FY2020FY2019FY2018FY2017
Price to earnings10.123.2-30.1-13.6-3.0-68.411.7-8.2
Price to sales2.84.66.09.56.31.81.83.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.